Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Huadong Med Acquires Rights To Bi-functional Immunotherapy in $75 Million Deal

publication date: Feb 9, 2022

Hangzhou's Huadong Medicine acquired Asia Pacific (ex-Japan) rights to a bi-functional immunotherapy from Akso Biopharma of Menlo Park, CA in a $75 million agreement. Akso's AB002, a pre-clinical stage candidate, includes a DEEP-engineered soluble PD-1 decoy receptor that traps PD-L2 and PD-L1 and an IL-15 agonist to activate natural killer cells. Huadong will be responsible for development in Asia, but the two companies will form a Joint Research Committee to oversee IND-enabling work. Huadong Medicine develops products for oncology, immunology, nephrology and diabetes indications. More details....

Stock Symbol: (SHZ: 000963)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.